Rechte & Gesellschaft
EMA: New treatment for relapsed lung cancer approved
The European Medicines Agency (EMA) has recommended granting marketing authorisation for Imdylltra (tarlatamab) for treatment of adults with relapsed extensive-stage small cell lung cancer. The recommendation is for use as a monotherapy. This decision provides a new option for patients with this aggressive type of cancer after relapse. The European Commission will now review the recommendation and decide whether to grant marketing authorisation.
New treatment option becomes available for relapsed small cell lung cancer patients.